UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 169

Sortiert nach

Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors

Journal of clinical oncology, 2010-09, Vol.28 (25), p.3965-3972

2010

Link zum Volltext

Verfügbarkeit prüfen

Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441

Cancer research (Chicago, Ill.), 2006-05, Vol.66 (10), p.5354-5362

2006

Link zum Volltext

Verfügbarkeit prüfen

Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma

Clinical cancer research, 2008-05, Vol.14 (10), p.2900-2908

2008

Link zum Volltext

Verfügbarkeit prüfen

Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors

Clinical cancer research, 2008-12, Vol.14 (23), p.7917-7923

2008

Link zum Volltext

Verfügbarkeit prüfen

The Potential of PARP Inhibitors in Genetic Breast and Ovarian Cancers

Annals of the New York Academy of Sciences, 2008-09, Vol.1138 (1), p.136-145

2008

Link zum Volltext

Verfügbarkeit prüfen

The clinical development of carboplatin – A personal perspective

Inorganica Chimica Acta, 2019-12, Vol.498, p.118987, Article 118987

Calvert, Hilary

2019

Link zum Volltext

Verfügbarkeit prüfen

Temozolomide and Treatment of Malignant Glioma

Clinical cancer research, 2000-07, Vol.6 (7), p.2585-2597

2000

Link zum Volltext

Verfügbarkeit prüfen

Targeting Poly(ADP-Ribose) Polymerase: A Two-Armed Strategy for Cancer Therapy

Clinical cancer research, 2007-11, Vol.13 (21), p.6252-6256

2007

Link zum Volltext

Verfügbarkeit prüfen

The Development of Phase I Cancer Trial Methodologies: the Use of Pharmacokinetic and Pharmacodynamic End Points Sets the Scene for Phase 0 Cancer Clinical Trials

Clinical cancer research, 2008-06, Vol.14 (12), p.3664-3669

2008

Link zum Volltext

Verfügbarkeit prüfen

Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors

Clinical cancer research, 2009-05, Vol.15 (9), p.3177-3183

2009

Link zum Volltext

Verfügbarkeit prüfen

A Phase I and Pharmacokinetic Study of Paclitaxel Poliglumex (XYOTAX), Investigating Both 3-Weekly and 2-Weekly Schedules

Clinical cancer research, 2005-11, Vol.11 (21), p.7834-7840

2005

Link zum Volltext

Verfügbarkeit prüfen

Novel Poly(ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatch Repair-Deficient Cells

Clinical cancer research, 2004-02, Vol.10 (3), p.881-889

2004

Link zum Volltext

Verfügbarkeit prüfen

Endpoints and other considerations in phase I studies of targeted anticancer therapy: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT)

European journal of cancer (1990), 2008-01, Vol.44 (1), p.19-24

2008

Link zum Volltext

Verfügbarkeit prüfen

Phase I Clinical and Pharmacokinetic Study of Pemetrexed and Carboplatin in Patients With Malignant Pleural Mesothelioma

Journal of clinical oncology, 2002-08, Vol.20 (16), p.3533-3544

2002

Link zum Volltext

Verfügbarkeit prüfen

Isoindolinone-based inhibitors of the MDM2–p53 protein–protein interaction

Bioorganic & medicinal chemistry letters, 2005-03, Vol.15 (5), p.1515-1520

2005

Link zum Volltext

Verfügbarkeit prüfen

Randomized Trial of Two Intravenous Schedules of the Topoisomerase I Inhibitor Liposomal Lurtotecan in Women With Relapsed Epithelial Ovarian Cancer: A Trial of the National Cancer Institute of Canada Clinical Trials Group

Journal of clinical oncology, 2005-03, Vol.23 (9), p.1859-1866

2005

Link zum Volltext

Verfügbarkeit prüfen

Resistance-Modifying Agents. 9. Synthesis and Biological Properties of Benzimidazole Inhibitors of the DNA Repair Enzyme Poly(ADP-ribose) Polymerase

Journal of medicinal chemistry, 2000-11, Vol.43 (22), p.4084-4097

2000

Link zum Volltext

Verfügbarkeit prüfen

Potentiation of Temozolomide and Topotecan Growth Inhibition and Cytotoxicity by Novel Poly(adenosine Diphosphoribose) Polymerase Inhibitors in a Panel of Human Tumor Cell Lines

Clinical cancer research, 2000-07, Vol.6 (7), p.2860-2867

2000

Link zum Volltext

Verfügbarkeit prüfen

Phase I and Pharmacokinetic Study of E7070, a Chloroindolyl-Sulfonamide Anticancer Agent, Administered on a Weekly Schedule to Patients with Solid Tumors

Clinical cancer research, 2003-11, Vol.9 (14), p.5195-5204

2003

Link zum Volltext

Verfügbarkeit prüfen

Design and conduct of early clinical studies of two or more targeted anticancer therapies: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies

European journal of cancer (1990), 2013-05, Vol.49 (8), p.1808-1814

2013

Link zum Volltext

Verfügbarkeit prüfen

Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy

Molecular cancer therapeutics, 2002-05, Vol.1 (7), p.545

2002

Link zum Volltext

Verfügbarkeit prüfen

A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation

Cancer chemotherapy and pharmacology, 2013-05, Vol.71 (5), p.1191-1199

2013

Link zum Volltext

Verfügbarkeit prüfen

Phase 0 clinical trials: Recommendations from the task force on methodology for the development of innovative cancer therapies

European journal of cancer (1990), 2009-03, Vol.45 (5), p.741-746

2009

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 169

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(156)
Mit Volltextzugriff
(156)

Publikationsform

Sprache

Englisch
(169)
Japanisch
(16)

Erscheinungsjahr

n.n

Thema

Science & Technology
(105)
Life Sciences & Biomedicine
(102)
Humans
(92)
Biological And Medical Sciences
(78)
Medical Sciences
(77)
Pharmacology. Drug Treatments
(70)
Oncology
(64)
Antineoplastic Agents
(63)
Female
(51)
Adult
(39)
Aged
(39)
Male
(39)
Middle Aged
(39)
Chemotherapy
(37)
Pharmacology & Pharmacy
(37)
Animals
(35)
Thymidylate Synthase - Antagonists & Inhibitors
(30)
Neoplasms - Drug Therapy
(29)
Mice
(27)
Structure-Activity Relationship
(25)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors

Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial

Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441

Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma

Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors

The Potential of PARP Inhibitors in Genetic Breast and Ovarian Cancers

The clinical development of carboplatin – A personal perspective

Temozolomide and Treatment of Malignant Glioma

Targeting Poly(ADP-Ribose) Polymerase: A Two-Armed Strategy for Cancer Therapy

The Development of Phase I Cancer Trial Methodologies: the Use of Pharmacokinetic and Pharmacodynamic End Points Sets the Scene for Phase 0 Cancer Clinical Trials

Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors

A Phase I and Pharmacokinetic Study of Paclitaxel Poliglumex (XYOTAX), Investigating Both 3-Weekly and 2-Weekly Schedules

Novel Poly(ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatch Repair-Deficient Cells

Endpoints and other considerations in phase I studies of targeted anticancer therapy: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT)

Phase I Clinical and Pharmacokinetic Study of Pemetrexed and Carboplatin in Patients With Malignant Pleural Mesothelioma

Population Pharmacokinetics and Pharmacodynamics of Paclitaxel and Carboplatin in Ovarian Cancer Patients: A Study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group

Isoindolinone-based inhibitors of the MDM2–p53 protein–protein interaction

Randomized Trial of Two Intravenous Schedules of the Topoisomerase I Inhibitor Liposomal Lurtotecan in Women With Relapsed Epithelial Ovarian Cancer: A Trial of the National Cancer Institute of Canada Clinical Trials Group

Resistance-Modifying Agents. 9. Synthesis and Biological Properties of Benzimidazole Inhibitors of the DNA Repair Enzyme Poly(ADP-ribose) Polymerase

Potentiation of Temozolomide and Topotecan Growth Inhibition and Cytotoxicity by Novel Poly(adenosine Diphosphoribose) Polymerase Inhibitors in a Panel of Human Tumor Cell Lines

Phase I and Pharmacokinetic Study of E7070, a Chloroindolyl-Sulfonamide Anticancer Agent, Administered on a Weekly Schedule to Patients with Solid Tumors

Design and conduct of early clinical studies of two or more targeted anticancer therapies: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies

Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy

A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation

Phase 0 clinical trials: Recommendations from the task force on methodology for the development of innovative cancer therapies

Suchergebnisse filtern